Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-23T02:01:07.977Z Has data issue: false hasContentIssue false

Part 1 - Anticancer Treatment Overview

Published online by Cambridge University Press:  10 August 2023

Monica Kathleen Wattana
Monica Kathleen Wattana
Affiliation:
University of Texas, MD Anderson Cancer Center
Get access

Summary

Defines terminology, an overview of cancer types, modes and locations of metastasis, cancer statistics, and treatment modalities.

Keywords

tumormetastasisleukemialymphomamyelomacarcinomasarcomacancermorbiditymortality
Type
Chapter
Information
Pocket Guide to Oncologic Emergencies , pp. 5 - 24
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

American Cancer Society. How Chemotherapy Drugs Work. [cited 2022 Dec 1]. Available from: www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-chemotherapy-drugs-work.htmlGoogle Scholar
Gao, Y, Shang, Q, Li, W, Guo, W, Stojadinovic, A, Mannion, C, Man, Y, Chen, T. Antibiotics for cancer treatment: A double-edged sword. Journal of Cancer. 2020;11(17):5135–5149.CrossRefGoogle ScholarPubMed
Malhotra, V, Perry, MC. Classical chemotherapy: Mechanisms, toxicities and the therapeutic window. Cancer Biology & Therapy. 2003 Mar;2(sup1):1–3.CrossRefGoogle ScholarPubMed
McBride, G. Researchers optimistic about targeted drugs for pancreatic cancer. JNCI Journal of the National Cancer Institute. 2004 Nov 2;96(21):1570–1572.CrossRefGoogle ScholarPubMed
Mukhtar, E, Adhami, VM, Mukhtar, H. Targeting microtubules by natural agents for cancer therapy. Molecular Cancer Therapeutics. 2014 Feb 1;13(2):275–284.CrossRefGoogle ScholarPubMed
National Cancer Institute. A to Z List of Cancer Drugs. [cited 2022 Dec 1]. Available from: www.cancer.gov/about-cancer/treatment/drugsGoogle Scholar

References

Bazinet, A, Popradi, G. A general practitioner’s guide to hematopoietic stem-cell transplantation. Current Oncology. 2019 Jun 1;26(3):187–191.CrossRefGoogle ScholarPubMed
Khaddour, K, Hana, CK, Mewawalla, P. Hematopoietic Stem Cell Transplantation [Internet]. NCBI Bookshelf. 2022 [cited 2022 Jul 28]. Available from: www.ncbi.nlm.nih.gov/books/NBK536951/Google Scholar
Randolph, BV, Ciurea, SO. What the Intensivist Needs to Know about Hematopoietic Stem Cell Transplantation? Oncologic Critical Care [Internet]. Cham: Springer International Publishing; 2019 [cited 2022 Jul 28]. pp. 1531–1546. Doi: 10.1007/978-3-319-74588-6_99.Google Scholar

References

Drăgănescu, M, Carmocan, C. Hormone therapy in breast cancer. Chirurgia. 2017;112(4):413.CrossRefGoogle ScholarPubMed
Hormone Therapy [Internet]. Endocrine Therapy. [cited 2022 Jul 24]. Available from: www.cancer.org/treatment/treatments-and-side-effects/treatment-types/hormone-therapy.htmlGoogle Scholar
Labrie, F. Hormonal Therapy of Prostate Cancer. Neuroendocrinology: Pathological Situations and Diseases [Internet]. Elsevier; 2010 [cited 2022 Jul 24]. pp. 321–341. Doi: 10.1016/s0079-6123(10)82014-x.CrossRefGoogle Scholar
Lee, YC, Lheureux, S, Oza, AM. Treatment strategies for endometrial cancer: Current practice and perspective. Current Opinion in Obstetrics and Gynecology. 2017 Feb;29(1):47–58.CrossRefGoogle ScholarPubMed

References

Garcia Borrega, J, Gödel, P, Rüger, MA, Onur, ÖA, Shimabukuro-Vornhagen, A, Kochanek, M, Böll, B. In the eye of the storm: Immune-mediated toxicities associated with CAR-T-Cell therapy. HemaSphere. 2019 Apr;3(2):e191.CrossRefGoogle ScholarPubMed
Riegler, LL, Jones, GP, Lee, DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Therapeutics and Clinical Risk Management. 2019 Feb; 15:323–335.CrossRefGoogle ScholarPubMed
Yeung, SJ, Qdaisat, A, Chaftari, P, Lipe, D, Merlin, J, Rajha, E, Wechsler, A, Sandoval, M, Viets, J, Al‐Breiki, A, Shah, M, Pandey, R, Kamal, M, Khattab, O, Toale, K, Wattana, M, Elsayem, A, Gaeta, S, Brock, P, Reyes‐Gibby, C, Alagappan, K. Diagnosis and management of immune‐related adverse effects of immune checkpoint therapy in the emergency department. Journal of the American College of Emergency Physicians Open. 2020 Aug 30;1(6):1637–1659.CrossRefGoogle ScholarPubMed

References

Brown, S, Kirkbride, P, Marshall, E. Radiotherapy in the acute medical setting. Clinical Medicine. 2015 Aug;15(4):382–387.CrossRefGoogle ScholarPubMed
Kirthi Koushik, AS, Harish, K, Avinash, HU. Principles of radiation oncology: A beams-eye view for a surgeon. Indian Journal of Surgical Oncology. 2013 Mar 19;4(3):255–262.CrossRefGoogle ScholarPubMed

References

Bedard, PL, Hyman, DM, Davids, MS, Siu, LL. Small molecules, big impact: 20 years of targeted therapy in oncology. The Lancet. 2020 Mar;395(10229):1078–1088.CrossRefGoogle ScholarPubMed
Cancer Research Institute. Immunotherapy [Internet]. [cited 2022 Jul 24]. Available from: www.cancerresearch.org/en-us/immunotherapy/treatment-types/targeted-antibodiesGoogle Scholar
Fricker, LD. Proteasome inhibitor drugs. Annual Review of Pharmacology and Toxicology. 2020 Jan 6;60(1):457–476.CrossRefGoogle ScholarPubMed
Hartmann, J, Haap, M, Kopp, H-G, Lipp, H-P. Tyrosine kinase inhibitors – A review on pharmacology, metabolism and side effects. Current Drug Metabolism. 2009 Jun 1;10(5):470–481.CrossRefGoogle ScholarPubMed
Steeghs, N, Nortier, JWR, Gelderblom, H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: An update of recent developments. Annals of Surgical Oncology. 2006 Nov 14;14(2):942–953.CrossRefGoogle ScholarPubMed
Targeted Therapies [Internet]. My Cancer Genome. Available from: www.mycancergenome.org/content/page/overview-of-targeted-therapies-for-cancer/Google Scholar
Wu, P, Nielsen, TE, Clausen, MH. FDA-approved small-molecule kinase inhibitors. Trends in Pharmacological Sciences. 2015 Jul;36(7):422–439.CrossRefGoogle ScholarPubMed
Zhou, G-B, Zhang, J, Wang, Z-Y, Chen, S-J, Chen, Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: A paradigm of synergistic molecular targeting therapy. Philosophical Transactions of the Royal Society B: Biological Sciences. 2007 Feb 22;362(1482):959–971.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×